Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

‘Durable Demand’: Pfizer CEO Expects $26B COVID-19 Vaccine Profits in 2021, Plans for Boosters

‘Durable Demand’: Pfizer CEO Expects $26B COVID-19 Vaccine Profits in 2021, Plans for Boosters

Pharmaceutical giant Pfizer is banking on COVID-19 being a major profit-driver for years to come as the company lines up vaccine delivery contracts for as far away as 2024. Corporate leaders have previously spoken of plans to dramatically increase the price of a jab once governments stop being the primary buyer.

In a first quarter earnings statement on Tuesday, Pfizer Chairman and CEO Albert Bourla said the company expects to make $26 billion in revenue from sales this year of the COVID-19 vaccine it jointly produced with German firm BioNTech. However, he expects that vaccine manufacturing will only increase in future years, with the company preparing to make 3 billion doses in 2022.

While some of those will be two-dose treatments for first-time recipients, the company also expects COVID-19 to become endemic and is increasingly expecting to deliver annual booster shots as well, which could potentially be tweaked to protect from whichever strain is expected to be dominant that year.

“Based on what we’ve seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome,” Bourla said. “It is our hope that the Pfizer-BioNTech vaccine will continue to have a global impact by helping to get the devastating pandemic under control and helping economies around the world not only open – but stay open – creating a scenario in which Pfizer can continue to be both a leader and a beneficiary.”

Multi-Year Contracts Unveiled


Bourla spelled out that Pfizer has already reached an agreement with Canada to deliver as many as 125 million doses in 2022 and 2023, with the option of another 60 million doses in 2024.

Canada’s population is just 37.6 million. According to government statistics, Ottawa has already spent more than $1 billion procuring as many as 180 million vaccines, including up to 76 million from Pfizer expected to begin shipping sometime this week, but also three others from Moderna, Johnson & Johnson, and AstraZeneca, the lattermost of which includes 2 million doses donated by the United States.

Bourla also said Pfizer has signed a deal to supply the United Kingdom with up to 60 million more doses in 2021 and to supply Israel with enough doses in 2022 “for the government to boost every eligible citizen, subject to local guidelines – with the option to purchase millions of additional doses for additional boosters.” It’s unclear if this is intended to include the millions of Palestinians who live under Israeli occupation but are not considered Israeli citizens and have not been given the same access to COVID-19 vaccines by Jerusalem.

The Times of Israel reported on Wednesday that Israel already has more than enough vaccines for its population and is expecting millions more doses to arrive, which it may give away to other nations but has also hinted may simply be thrown away. Meanwhile, less than 1% of Palestinians have been fully vaccinated, most of whom are workers who come into daily contact with Israelis because, as the paper put it, “Israel does not believe it is legally required to vaccinate the Palestinians.”

Bourla also noted that younger age cohorts were also being tested for vaccination: ages 2 to 5, 5 to 11, and 12 to 16, with another test on six-month-olds to two-year-olds expected later this year. Data from the other tests is expected before the end of the summer.

Not all of the benefits for Pfizer will come from the vaccine itself, though: the research behind the new mRNA vaccine design has yielded gains on new fronts, including flu shots and antiviral treatments, and could potentially be applied to treating other rare diseases like the autoimmune disease alopecia areata. Pfizer is also looking at creating an antiviral treatment for COVID-19 to be administered as either a shot or a pill to people who have contracted the disease, similarly to influenza antivirals.

Unequal Access for Third World


Pfizer CFO Frank D’Amelio also said in the Tuesday meeting that as a percentage of total company revenue, the COVID-19 vaccine has increased to 36% from the 25% projection made at the start of the year. He noted Pfizer expects to make 2.5 billion doses in 2021 and has contracted to deliver 1.6 billion doses this year.

At present, Pfizer’s money from COVID-19 vaccines is derived purely from government contracts. The company offers three tiers of prices depending on the relative wealth of the buying country, D’Amelio said on the Tuesday call. It’s unclear how disparate those prices are, but a high-wealth country paid $19.50 per shot while Malaysia, ranked 36th in the world by gross domestic product, paid the equivalent of $18.79 per shot.

Other nations have not been so lucky. One unnamed Latin American nation, which could not be identified due to a confidentiality agreement signed with Pfizer, had to agree to bear the costs of lawsuits against Pfizer for adverse effects of the COVID-19 vaccines, according to the Bureau of Investigative Journalism. Negotiations with Brazil and Argentina fell apart, according to the report, after Pfizer demanded they put up sovereign wealth assets like embassies and military bases as collateral against future legal cases.

An official from the unnamed country told TBIJ the negotiations with Pfizer felt like “high-level bullying” and that it felt like the health of their citizens were being “held to ransom.”

Coming Price Hike Amid Anti-TRIPS Push


In a February call with Wall Street investors, D’Amelio indicated that the company’s pricing will change significantly once governments stop being their primary customer and the company can excusably increase prices to match their other vaccines. While Pfizer is presently getting $19.50 per dose in the US, he noted that “that’s not a normal price, like we typically get for a vaccine - $150, $175 per dose ... Let's go beyond a pandemic pricing environment, the environment we're currently in: Obviously, we're going to get more on price.”

That amounts to a nearly 900% increase over present prices. It’s no coincidence either, then, that Pfizer has very strongly opposed the movement by more than 80 Global South nations, led by India and South Africa, to convince the World Trade Organization to waive intellectual property laws with regard to COVID-19 vaccines. The Trade-Related Aspects of Intellectual Property (TRIPS) agreement put in place in 1995 globalized IP laws, making the manufacture of cheap generic versions of drugs all but impossible.

TRIPS came just as the first anti-HIV/AIDS drugs entered the market and as the virus spread across Africa, leaving the world’s poorest nations totally unable to afford life-saving drugs that were priced so high that even First World customers found them prohibitively expensive. AIDS deaths didn’t peak for another decade, reaching in 2004 more than twice the number of deaths as in 1995, with an estimated 1.7 million people dying of AIDS complications that year.

On Wednesday afternoon, US Trade Representative Katherine Tai announced that the Biden administration was coming out in support of patent waivers for COVID-19 vaccines, saying they were presently in negotiation with the WTO over the matter.

“This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures,” Tai said in a press release.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
A monster hit and a billion-dollar toy empire
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
Canada: Nurse Suspended and Fined 93 Thousand Dollars After Stating the World’s Most Well-Known Fact Since the Creation of Adam and Eve, That There Are Only Two Genders
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
U.S. Treasury Secretary Whitney Bessent Backs Stablecoins to Boost Treasury Demand
Spain to Declare Disaster Zones After Massive Wildfires
Three-Minute Battery Swap Touted as Future of EVs
Beijing Military Parade to Showcase Weapons Advances
U.S. Tech Stocks Slide on AI Boom Concerns
White House Confirms Talks Over Intel Stake
Trump Suggests U.S. Could Support Ukraine ‘By Air’
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
UK Government Tries to Sue 4chan for Breaching Online Safety Act
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Miles Worth Billions: How Airlines Generate Huge Profits
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
"Every Centimeter of Your Body Is a Masterpiece": The Shocking Meta Document Revealed
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
Beijing is moving into gold and other assets, diversifying away from the dollar
China Requires Data Centres to Source Majority of AI Chips Locally, For Technological Sovereignty
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
Trump Backs Putin’s Land-for-Peace Proposal Amid Kyiv’s Rejection
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
Jellyfish Swarm Triggers Shutdown at Gravelines Nuclear Power Station in Northern France
OpenAI’s ‘PhD-Level’ ChatGPT 5 Stumbles, Struggles to Even Label a Map
Zelenskyy to Visit Washington after Trump–Putin Summit Yields No Agreement
×